These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 3718817

  • 41. Isolation and preliminary characterization of an Adriamycin-resistant murine fibrosarcoma cell line.
    Giavazzi R, Scholar E, Hart IR.
    Cancer Res; 1983 May; 43(5):2216-22. PubMed ID: 6831444
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxy-morpholynil-doxorubicin.
    Michieli M, Damiani D, Michelutti A, Melli C, Ermacora A, Geromin A, Fanin R, Russo D, Baccarani M.
    Haematologica; 1996 May; 81(4):295-301. PubMed ID: 8870372
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Glutathione S-transferase and glutathione peroxidase are essential in the early stage of adriamycin resistance before P-glycoprotein overexpression in HOB1 lymphoma cells.
    Lee WP, Lee CL, Lin HC.
    Cancer Chemother Pharmacol; 1996 May; 38(1):45-51. PubMed ID: 8603451
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Influence of lipophilicity on cytotoxicity of anthracyclines in LoVo and LoVo/Dx human cell lines.
    Facchetti I, Grandi M, Cucchi P, Geroni C, Penco S, Vigevani A.
    Anticancer Drug Des; 1991 Nov; 6(5):385-97. PubMed ID: 1764162
    [Abstract] [Full Text] [Related]

  • 51. Intensely potent doxorubicin analogues: structure-activity relationship.
    Farquhar D, Cherif A, Bakina E, Nelson JA.
    J Med Chem; 1998 Mar 12; 41(6):965-72. PubMed ID: 9526570
    [Abstract] [Full Text] [Related]

  • 52. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
    Florent JC, Dong X, Gaudel G, Mitaku S, Monneret C, Gesson JP, Jacquesy JC, Mondon M, Renoux B, Andrianomenjanahary S, Michel S, Koch M, Tillequin F, Gerken M, Czech J, Straub R, Bosslet K.
    J Med Chem; 1998 Sep 10; 41(19):3572-81. PubMed ID: 9733483
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Synthesis and antitumor activity of 9-[(carbamoyloxy)alkyl]anthracyclines: a novel class of anthracycline derivatives.
    Adams N, Blake C, Broadhurst MJ, Bushnell DJ, Hassall CH, Hartmann HR, Keech E, Stratton AR, Thomas GJ.
    J Med Chem; 1990 Sep 10; 33(9):2380-4. PubMed ID: 2391682
    [Abstract] [Full Text] [Related]

  • 55. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.
    Zou Y, Ling YH, Van NT, Priebe W, Perez-Soler R.
    Cancer Res; 1994 Mar 15; 54(6):1479-84. PubMed ID: 8137251
    [Abstract] [Full Text] [Related]

  • 56. Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukemia.
    Inaba M, Johnson RK.
    Cancer Res; 1977 Dec 15; 37(12):4629-34. PubMed ID: 922743
    [Abstract] [Full Text] [Related]

  • 57. Comparative cytotoxicity of adriamycin, mitoxantrone and bisantrene as measured by a human tumor cloning system.
    Cowan JD, Von Hoff DD, Clark GM.
    Invest New Drugs; 1983 Dec 15; 1(2):139-44. PubMed ID: 6678863
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.